Saturday 17 October 2026
Export PRPH’s income statement to Excel — free account
ProPhase Labs, Inc.
PRPH Healthcare Diagnostics & Research
In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.
0.01
0.00
0.00%
Follow PRPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.40 | 0.33 | 0.88 | 3.78 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.17) | (1.48) | (3.11) | (5.48) | |
P/B ratio |
0.00 | 0.00 | 1.09 | 2.79 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.19 | 2.04 | 2.19 | 4.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.25) | (1.21) | (1.14) | (1.94) | |
EV/FCF |
(1.25) | (1.23) | (1.16) | (1.95) | |
Quick Ratio |
0.03 | 0.03 | 0.03 | 0.07 | |
Current Ratio |
0.05 | 0.06 | 0.06 | 0.14 | |
Net Debt/EBITDA |
(6.13) | (4.99) | (4.26) | (0.55) | |
Debt/Assets |
9.88% | 9.97% | 9.68% | 2.92% | |
Debt/Equity |
(1.82) | (9.54) | 1.65 | 0.28 | |
Asset Turnover |
0.06 | 0.06 | 0.07 | 0.06 | |
Operating CF/Net income |
0.03 | 0.14 | 0.17 | 0.51 | |
Capex/Depreciation |
0.00 | 0.01 | 0.00 | 0.00 | |
Interest Coverage |
(3.34) | (4.00) | (1.34) | (3.08) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.68% | |
Selling, General and Administrative Expense of Revenue |
283.98% | 579.92% | 761.86% | 524.92% | |
Intangible Assets out of Total Assets |
0.17 | 0.18 | 0.19 | 0.18 | |
Share Based Compensation of Revenue |
37.09% | 81.59% | 55.23% | 48.81% | |
Graham Net Nets |
(45.76) | (50.73) | (13.93) | (2.67) | |
Graham Number |
3.45 | 1.92 | 0.00 | 0.00 | |
Earnings Yield |
(2,655.11%) | (3,632.89%) | (386.58%) | (389.80%) | |
Free Cash Flow Yield |
(438.39%) | (508.06%) | (215.29%) | (55.22%) | |
Revenue per Share |
0.07 | 0.04 | 0.09 | 0.21 | |
Operating CF per Share |
(0.01) | (0.06) | (0.14) | (0.84) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | (0.06) | (0.14) | (0.84) | |
Cash per Share |
0.00 | 0.00 | 0.01 | 0.10 | |
Shareholders Equity per Share |
(0.22) | (0.05) | 0.41 | 1.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.22) | (0.05) | 0.41 | 1.65 | |
Free Cash Flow |
(0.08) | (0.74) | (1.23) | (3.49) | |
Working Capital |
(55.28) | (52.99) | (49.93) | (47.51) | |
Capital Expenditures |
0.00 | 0.01 | 0.00 | 0.00 | |
Net Current Asset Value |
(57.72) | (56.23) | (53.21) | (51.07) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.03) | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.81 | 10.87 | 10.80 | 17.46 | |
Average Payables |
29.20 | 27.53 | 27.14 | 28.65 | |
Average Inventory |
0.45 | 0.61 | 0.61 | 2.12 | |
Average Assets |
49.73 | 54.42 | 61.54 | 78.76 | |
Average Common Equity |
4.16 | 7.25 | 5.43 | 22.49 |
Columns are period end dates